CD8A and neoplasm: Pellegrini and colleagues evidenced that IL-7 treatment in combination with a virus-based vaccine lead to a 3.5-10 fold increase in the number of CD4+ and CD8+ T cells in tumor-bearing mice, as well as higher infiltration levels of T lymphocytes in the tumor milieu compared with the PBS treatment group (83).